Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.53 |
| ▸ | MASP2 | O00187 | 1/20 | 0.53 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | GPR3 | P46089 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887071 | 0.79 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL577953 | 0.78 | NPC1 (0.52) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL30014118 | 0.78 | NPC1 (0.52) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL1590490 | 0.76 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL3253183 | 0.76 | ALDH1A1 (0.48) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| Benzoylenurea SCHEMBL4559940 | 0.76 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL6856197 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL30013315 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL4288877 | 0.76 | PDE10A (0.44) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL11332812 | 0.75 | NPC1 (0.61) | ALDH1A1KDM4ELMNAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109422697-A | The method for synthesizing Quinazol derivative | 南京理工大学 | 2019-03-05 | — | — | CN | claimed |
| US-4226994-A | BUTANOL SOLVENT, ANTHRANILIC ACID, CYANAMIDE, HYDRAZINE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-10-07 | — | — | US | claimed |
| CN-120157674-A | New preparation method of domperidone | 刘辉 | 2025-06-17 | — | — | CN | disclosed |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | 858 THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023224998-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-3618829-B1 | QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-110612100-B | Quinazoline-pyridine derivatives for the treatment of diseases associated with cancer | 艾库斯生物科学有限公司 | 2023-04-14 | — | — | CN | disclosed |
| EP-4023293-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023293-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2022-07-06 | — | — | EP | disclosed |
| CN-114650986-A | 2-aminoquinazolinone derivatives | 住友制药株式会社 | 2022-06-21 | — | — | CN | disclosed |
| EP-1407774-A1 | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds | LION Bioscience AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1407774-A1 | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds | LION Bioscience AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2004024162-A1 | 2-AMINO-4-QUINAZOLINONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2004-03-25 | — | — | WO | disclosed |
| US-6525061-B1 | Combinatorial libraries for drug discovery;4-((6-bromo-4-oxo-1,4-dihydroquinazolin-2-yl)amino)b enzoic acid, | WYETH | 2003-02-25 | — | — | US | disclosed |
| EP-0185618-A2 | Isoindolines, process for their manufacture and their use | CIBA-GEIGY AG (CH) | 1986-06-25 | — | — | EP | disclosed |
| EP-0000737-B1 | MONOAZO PIGMENTS OF THE ACETOACETYLAMINO BENZIMIDAZOLONE SERIES, THEIR PREPARATION AND THEIR USE FOR COLOURING ORGANIC MATERIAL OF HIGH MOLECULAR WEIGHT | CIBA-GEIGY AG (CH) | 1981-04-29 | — | — | EP | disclosed |
| US-4226994-A | BUTANOL SOLVENT, ANTHRANILIC ACID, CYANAMIDE, HYDRAZINE | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-10-07 | — | — | US | disclosed |
| EP-0000737-A1 | Monoazo pigments of the acetoacetylamino benzimidazolone series, their preparation and their use for colouring organic material of high molecular weight | CIBA-GEIGY AG (CH) | 1979-02-21 | — | — | EP | disclosed |
| US-4052377-A | PIGMENTS | BASF AKTIENGESELLSCHAFT (DT) | 1977-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | ALDH1A1 4379/4885MEN1 1353/4885KMT2A 2794/4885 |
| US-11939335-B2 | Substituted imidazo[1,2-a]quinazolines and imidazo [1,2-a]pyrido[4,3-e]pyrimidines as inhibitors of PARG | PARG, PTGIS, PLG | ALDH1A1 2121/4885MEN1 1173/4885KMT2A 1646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.